Case: Semaglutide-Induced Immune-Mediated Necrotizing Myopathy — A Rare Autoimmune Side Effect
A case of immune-mediated necrotizing myopathy (IMNM) was reported following semaglutide treatment, representing a rare but serious autoimmune adverse event requiring clinical awareness.
Quick Facts
What This Study Found
IMNM (immune-mediated necrotizing myopathy) following semaglutide — rare autoimmune muscle adverse event requiring clinical awareness for unexplained weakness during GLP-1 therapy.
Key Numbers
How They Did This
Case report of IMNM developing after semaglutide initiation, with clinical documentation and immunological workup.
Why This Research Matters
Rare autoimmune events with widely prescribed drugs must be documented. Muscle weakness on GLP-1 drugs should trigger IMNM consideration.
The Bigger Picture
GLP-1 drugs are immunomodulatory — usually beneficially, but rarely triggering autoimmune conditions like IMNM.
What This Study Doesn't Tell Us
Single case. Cannot prove causation. IMNM has multiple triggers.
Questions This Raises
- ?How common is semaglutide-associated IMNM?
- ?Should muscle enzymes be monitored during GLP-1 therapy?
- ?Would stopping semaglutide and treating IMNM resolve the myopathy?
Trust & Context
- Key Stat:
- Rare autoimmune reaction Semaglutide's immunomodulatory effects rarely trigger autoimmunity — clinicians should consider IMNM in patients developing unexplained muscle weakness
- Evidence Grade:
- Case report of rare adverse event.
- Study Age:
- Published in 2025.
- Original Title:
- Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor?
- Published In:
- BMJ case reports, 19(3) (2026)
- Database ID:
- RPEP-15478
Evidence Hierarchy
Frequently Asked Questions
Can semaglutide cause muscle disease?
Very rarely. This case report documents immune-mediated necrotizing myopathy (IMNM), an autoimmune muscle condition, developing after semaglutide. If you develop unexplained muscle weakness on GLP-1 drugs, tell your doctor.
Is this common?
Extremely rare. However, clinicians should be aware that GLP-1 drugs' immunomodulatory effects can occasionally trigger autoimmune reactions. Most patients have no muscle problems.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15478APA
Lam, Brian; Tiniakou, Eleni; Zhang, Xinhai Robert; Assassi, Shervin. (2026). Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor?. BMJ case reports, 19(3). https://doi.org/10.1136/bcr-2025-269690
MLA
Lam, Brian, et al. "Immune-mediated necrotising myopathy following semaglutide treatment: a contributing factor?." BMJ case reports, 2026. https://doi.org/10.1136/bcr-2025-269690
RethinkPeptides
RethinkPeptides Research Database. "Immune-mediated necrotising myopathy following semaglutide t..." RPEP-15478. Retrieved from https://rethinkpeptides.com/research/lam-2026-immunemediated-necrotising-myopathy-following
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.